BioSpace News Archive

TransMedics Group, Inc. announced that is has acquired from Bridge to Life Ltd., assets and intellectual property related to the Ex-Vivo Organ Support System and LifeCradle Heart Preservation Transport System technologies.

Paratek Pharmaceuticals, Inc. announced that it has filed definitive proxy materials and a letter to Paratek stockholders with the U.S. Securities and Exchange Commission in connection with the Company’s previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.

MIRA Pharmaceuticals, Inc. announced the pricing of its initial public offering of 1,275,000 shares of common stock at an initial public offering price of $7.00 per share for aggregate gross proceeds of $8.9 million, prior to deducting underwriting discounts, commissions and other offering expenses.

Arbele presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough conference in Yokohama, Japan.

SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board, comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.

Lantern Pharma Inc. today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 2023.

LENSAR, Inc. today announced that the Company’s second quarter 2023 financial results will be released before market open on Wednesday, August 9, 2023.

Click Therapeutics, Inc. today announced the launch of its second active randomized clinical trial in migraine, ReMMiD-C, Reduction in Monthly Migraine Days-CGRP study, a fully remote and decentralized trial designed to investigate the efficacy and safety of digital therapeutics in reducing the number of monthly migraine days for adults diagnosed with episodic migraine currently receiving Calcitonin-Gene-Related Peptide (CGRP) inhibitor therapy.

Cyclo Therapeutics, Inc. today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock.

MyMD Pharmaceuticals, Inc. announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week.